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 An efficient GC-MS method is validated for a panel of 18 urinary steroids 
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GnRH; gonadotropin-releasing hormone 
LOD: limit of detection 
LOQ: limit of quantification 
MSTFA: N-Methyl-N-(trimethylsilyl)trifluoroacetamide 
PCa: prostatic carcinoma 
PLS: partial least squares 
PSA: prostate specific antigene  
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TRUS: trans-rectal ultrasound guided  
USP: urinary steroid profile 
No "Human Genes" is discussed in the paper.  
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ABSTRACT 
The biosynthesis of endogenous androgenic anabolic steroids (EAAS) in males varies with age. 
Knowledge of the general urinary EAAS profile’s dependence from aging - not reported up to now - 
may represents a prerequisite for its exploitation in the screening and diagnostic support for several 
pathologies. Extended urinary EAAS profiles were obtained from healthy and pathological 
individuals, using a GC-MS method which was fully validated by a stepwise, analyst-independent 
scheme. Seventeen EAAS and five of their concentration ratios were determined and investigated 
using multivariate statistical methods. A regression model based on Kernel partial least squares 
algorithm was built to correlate the chronological age of healthy male individuals with their 
“physiological age” as determined from their urinary EAAS profile. Strong correlation (R2=0.75; 
slope=0.747) and good prediction ability of the real chronological age was inferred from EAAS 
data. In contrast, patients with recent diagnosis (not pharmacologically treated) of prostatic 
carcinoma (PCa) exhibited a comprehensive EAAS profile with strong negative deviation from the 
model, corresponding a younger predicted age. This result is possibly related to the activation of 
anomalous steroid biosynthesis induced from PCa. Over a restricted 60-80 years-old population, 
PLS-discriminant analysis (DA) was used to distinguish healthy subjects from patients with 
untreated PCa. PLS-DA yielded excellent discrimination (sensitivity and specificity > 90%) 
between healthy and pathological individuals. This proof-of-concept study provides a preliminary 
evaluation of multivariate DA on wide EAAS profiles as a screening method to distinguish PCa 
from non-pathological conditions, overcoming the potentially interfering effect of ageing. 
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1. INTRODUCTION 
 
Sex hormones synthesis is regulated by the pulsating release of the hypothalamic gonadotropin-
releasing hormone (GnRH) [1]. Testosterone (T) and epitestosterone (E) are produced inside the 
Leydig cells and converted in peripheral tissues to dihydrotestosterone (DHT), which accounts for 
most of T biological action [2]. Adrenal androgens dehydroepiandrosterone (DHEA) and 
androstenedione are produced in the so-called zona reticulata of the adrenal cortex [3]. T undergoes 
extensive metabolic transformation before being excreted. In urine, the most abundant phase I 
metabolites of T are DHT, 5α-androstan-3α,17β-diol (5α-adiol), 5β-androstan-3α,17β-diol (5β-
adiol), androsterone (A) and etiocholanolone (Etio) [4], together with dehydroepiandrosterone 
(DHEA), the testosterone precursor. In particular, high concentrations of A and Etio are detected 
[5]. Many other minor metabolites complete the urinary steroid profile (USP) [6–10]. 
One of the main factors for the USP inter-individual variability lies in the polymorphism of an 
enzyme belonging to the 2B subfamily of the (UDP)-glucuronosyl transferases UGT’s subfamily 
2B, the UGT2B17, principal responsible of the androgens glucuronidation [11]. The frequency of 
the UGT2B17 (del/del) genotype varies widely among ethnic backgrounds, showing higher 
frequency in East Asian population [12]. It is associated with variation in urine testosterone [13], 
with consequent bimodal distribution of its excretion as well as large differences in androgen 
excretion between Asians and Caucasians [11]. Beside the inter-individual variability associated 
with genetic polymorphism, the specific USP of each individual may be altered by a variety of 
causes, including the intake of interfering drugs and the onset of pathological conditions, making its 
definition a potential diagnostic tool of interest. T and DHT are significant for the development of 
sexual characters [14] whereas a significant T drop is associated with ageing. In the early seventies, 
several authors reported an age-associated decline of serum testosterone levels from the fourth/fifth 
decade of life [15,16]. Analogous age-dependence was observed for the serum levels of DHEA and 
its sulphated metabolite, while DHT is not apparently modified in elderly men [15]. Besides T and 
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few other precursors, there is a lack of scientific literature about the evolution of other excreted 
endogenous androgenic steroids and T metabolites with ageing, partly because their concentration 
depends on the circadian rhythm and other scarcely predictable factors [14–16]. On the other hand, 
some of their concentration ratios, i.e. T/E, A/T, A/Etio, 5α-adiol/5β-adiol and 5α-adiol/E, proved to 
be more stable and are consistently used in doping control [10,17]. The same ratios could be 
possibly included among the variables monitored in the USP models, in order to verify whether 
these urinary steroid concentration ratios used in the steroid profile of professional athletes to test 
illicit administration of anabolic steroids (called the “steroidal module of the athlete biological 
passport”) may play a role also in the detection of the metabolic changes related with different 
causes, for example aging or prostatic malignancies, as in the present study. 
Recently, our [18] and other research groups [19,20] proposed to interpret the results of an urinary 
endogenous steroids panel using the methods of multivariate statistical analysis, with the purpose to 
ascertain the intake of androgenic drugs [21,22] or even the deceitful substitution of urine samples 
in anti-doping controls [18]. The possible application to extended USP of similar multivariate 
statistical methods aimed to single out pathologies that modify the sexual hormones balance, among 
which prostatic carcinoma (PCa) [23], is interfered by the large inter-individual variability of 
steroid profiles due to genetic polymorphism and the general factors that modify them, including 
ageing. At least the latter variability factor can be tentatively rationalized by studying the 
characteristic changes induced by ageing on the steroid profile. Modelling the aging effect on the 
USP general variance may allow further inference on a general population of healthy and 
pathological subjects. On the other hand, the incidence of PCa generally increases with increasing 
age, with the largest percentage of diagnosed cases found in men 65-74 years old [23]. Since the 
correlation between PCa and increased levels of the most important androgens is well known [25], 
and considering the non-invasiveness of urine sampling, we decided to investigate the effectiveness 
of the USP for diagnosis of prostatic carcinoma using a simple GC-MS method combined with 
multivariate statistics.. 
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A recent review by Bax et al. [24] provides an overview of the innovative approaches under study 
to improve the diagnosis of PCa. They can be grouped essentially as follows: (a) sensorial analysis 
(which relies on the mammalian sense of smell), (b) senso-instrumental analysis and (c) chemical 
analysis. The teams working with targeted chemical analysis found out that sarcosine, amino acids, 
and amines could represent powerful biomarkers for PCa. In particular, Derezinski et al. produced a 
Partial Least Squares – Discriminant Analysis (PLS-DA) model using a pool of amino-acids which 
yielded an accuracy exceeding 82 %. In the present study, we built a regression model that could 
predict the chronological age of healthy individuals according to their deconjugated steroidal 
profile, composed of 17 target steroids, and considered altogether as a multivariate dataset. This 
regression model explores the relationship existing between the physiological modification of the 
urinary steroid profile and the ageing of male individuals. A similar regression - purposely 
optimized - was preliminarily used to highlight systematic deviations from the model caused by 
ongoing pathologies that may affect the male hormone balance, in particular prostatic carcinoma 
(PCa). Individuals suffering from PCa, but still not under therapy, have been enrolled for this 
preliminary study. The prediction capability of this regression model was tested by discriminant 
analysis. 
 
2. MATERIAL AND METHODS 
 
2.1 CHEMICALS AND REAGENTS 
 
 All steroid standards were purchased as pure powders from Steraloids (Newport, RI, USA); DHT 
was provided by LGC Promochem (Milan, Italy). Methanol, methyl tert-butyl ether (TBME), ethyl 
acetate, 17α-methyltestosterone, dithioerythritol and N-Methyl-N-(trimethylsilyl)trifluoroacetamide 
(MSTFA) were provided by Sigma-Aldrich (Milan, Italy). β-glucuronidase from Escherichia Coli 
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was purchased from Roche Life Science (Indianapolis, IN, USA). Ultra-pure water was obtained 
using a Milli-Q® UF-Plus apparatus (Millipore, Bedford, MA, USA).  
Standards solutions were prepared in methanol at the concentration of 1 mg/mL. Then, three 
working solution mixtures were prepared by dilution. Two internal standards were used: 
testosterone-d3 served for the quantification of all the target analytes, with the exception of A and 
Etio which were quantified by 17α-methyltestosterone. The list of the studied steroids, together with 
details about each working solution are reported in Table 1. All standard solutions were stored at 
10°C until used. 
 
2.2 EXPERIMENTAL DESIGN 
 
A GC-MS method for the detection of 8 EAAS was validated in a previous study [18]. In the 
present study, a faster sample pre-treatment was optimized by means of design of experiment (DoE) 
[26], with the main objective of removing the SPE extraction step, following the experience of 
others research groups on similar ranges of target analytes [5,6,10]. 
Three critical factors were identified, namely (i) the optimal volume of β-glucuronidase enzyme 
used in the deconjugation step, within the experimental domain 50-100 μL, (ii) the solvent used for 
the extraction of the de-conjugated analytes (pentane and TBME were tested) (iii) the reaction time 
(30 to 50 minutes) allowed for the derivatization of the target analytes by MSTFA. A two levels full 
factorial DoE was employed plus one central point, giving a total of 9 experiments, performed in 
triplicate for a total number of 27 experiments (Supplemental Material – Table 1). The central point 
conditions were set as the middle values of quantitative parameters, together with a 1:1 (v/v) 
pentane - TBME mixture for the extraction. The testing solutions contained 125 ng/mL of MIX A 
analytes and 2250 ng/mL of MIX B analytes (see Table 1). MIX C was also added to the solution at 
the concentration of 125 ng/mL in order to test the enzymatic activity. The software R-3.4.2 was 
employed to perform the model computation [27,28]. 
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2.3 SAMPLE PREPARATION AND ANALYTICAL METHOD 
 
The sample preparation involved the fortification of 6 mL of urine with testosterone-d3 and 17α-
methyltestosterone at the final concentration of respectively 25 ng/mL and 125 ng/mL. The pH was 
adjusted to 7.5 by adding 2 mL of a 0.1 M phosphate buffer and some drops of NaOH 1 N. 100 μL 
of β-glucuronidase (corresponding to approximately 83 units) was subsequently added and the 
mixture was incubated at 58°C for 1 hour. Once the hydrolysis was completed, the mixture was 
cooled to room temperature and 2 mL of 0.1 M carbonate buffer (pH 9) were added. LLE was 
performed with 10 mL of TBME. Then, the sample was shaken in a multi-mixer for 10 minutes and 
subjected to centrifugation at 4000 rpm for 5 minutes. The organic phase was transferred into a vial 
and dried under nitrogen at 70°C. The dry residue was reacted with 50 μL of 
MSTFA/NH4I/dithioerythritol (1.000:2:4 v/w/w) solution for 30 minutes at 70°C. A 1 μL aliquot of 
the resulting solution was injected into the GC-MS system working in the splitless mode. A typical 
chromatogram is reported in Figure 1 of the Supplemental Material. 
The possible occurrence of urine sample degradation is associated with an increased amount of 5β-
androstan-3,17-dione combined with a decrease of etiocholanolone concentration [29]. To assess 
the integrity of the samples, the same criterion adopted by the WADA [17] was used, e.g.  a 5β-
androstan-3,17-dione/Etio ratio higher than 0.1 was used as an indicator of significant microbial 
degradation and implied to discard the sample. 
The specific gravity (SG) of each sample was measured, and the concentrations of all analytes were 
normalized for the dilution factor against the SG reference value of 1.020: 
Conccorrect = Concmeasured×(1.020-1)/(SG-1). 
 
2.4 INSTRUMENTATION 
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Details about GC-MS instrumentation and operating conditions are reported in a previous study 
[18]. The MS was operated in the selected ion monitoring mode, and three diagnostic ions for each 
analyte were monitored with dwell times of 20-50 ms (Supplemental Material – Table 2).  
The SG was measured with an Automatic Urinalysis System FUS-100/H800 (DIRUI Industrial, 
China) using a refractometric method. 
 
2.5 METHOD VALIDATION 
The calibration process was conducted with an optimized procedure, requiring the preparation of 
two replicates of the calibration curves for the 18 targeted steroids in three different days for a total 
of six calibration curves [30]. Several validation parameters could be determined from these data, 
including linearity range, selectivity, specificity, limit of detection (LOD), limit of quantification 
(LOQ) trueness, intra and inter-assay precision, and repeatability. The data from each specific 
calibration curve were quantified using a calibration curve obtained in a different day, allowing to 
manage each set of data as independent. Therefore, 6 samples (from 6 different batches) per each 
calibration level were employed to estimate the previously cited validation parameters. Matrix 
effect, extraction recovery, and carry-over were calculated with separate experiments and regularly 
checked within daily working sessions. The linearity was evaluated within the concentration range 
of 2.0-500.0 ng/mL for the MIX A analytes (two independent calibration ranges were tested as 
follows: 2.0-125.0 ng/mL and 10.0-500.0 ng/mL – i.e. 2.0, 5.0, 10.0, 25.0, 50.0, 125.0, 250.0 and 
500 ng/mL) and within the range of 100.0–5000.0 ng/mL for the MIX B (calibration ranges: 100.0-
1500.0 ng/mL and 500.0-5000.0 ng/mL – i.e. 100.0, 200.0, 500.0, 1000.0, 1500.0, 2250.0, 3500.0 
and 5000.0 ng/mL). The lowest concentration ranges typically correspond to the expected 
physiological levels [5]. The linear calibration parameters were evaluated using the least squares 
regression method; several significance tests were performed to evaluate linearity, including lack-
of-fit tests, analysis of variance (ANOVA), Mandel's test, homo- vs. heteroscedasticity tests. 
Determination coefficient (R
2
), relative standard deviation of the slope, normality of the 
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standardized residuals, and deviation from back-calculated concentrations were also evaluated. In-
house spreadsheets, as well as package mvtnorm [31,32], and the routines developed by B. 
Desharnais et al. [30], working in the R environment, were used for this purpose. The LOD and 
LOQ were estimated by means of the Hubaux-Vos' algorithm [33]. 
To determine selectivity and specificity, the signal-to-noise ratio (S/N > 3) was measured on the 
selected ion chromatograms at the expected retention times for all the analytes of interest. The 
presence of interfering peaks around the retention time of the analytes was examined. Trueness, 
intra- and inter-assay precision were estimated as CV% and percent bias, respectively; satisfactory 
results were expected to lie within ±15%. Retention time repeatability was verified on 30 real urine 
samples together with blank water samples spiked at different concentration levels. Deviations 
below 1% from calibrators and controls were considered acceptable. Ion abundance repeatability 
was evaluated on the selected qualifying-ion chromatogram for each target analyte, with acceptance 
limit of ±20% with respect to the control. Carry-over effect was evaluated by injecting one distilled 
water extracts after the highest point of each calibration curve: if the signal-to-noise ratio was lower 
than 3 for in each ion chromatogram the carry-over effects was considered negligible. 
The matrix effect was estimated at three concentration levels by comparing the experimental results 
obtained from blank urine samples (collected from a 5 months old female child) and blank 
deionized water samples, both spiked after the extraction step [34]. The matrix effect for each target 
analyte was expressed as the percentage ratio between the two measured concentrations. The 
extraction recovery was determined by comparing the experimental results from blank urine 
samples spiked respectively before and after the extraction step and was expressed as the percentage 
ratio between the two quantified concentrations. 
 
2.6 SAMPLE COLLECTION 
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Single urine samples were collected from 241 Caucasian male volunteers, enrolled at the 
Department of Urology at the San Luigi Hospital of Orbassano (TO). They are subdivided as 
follow: (i) 212 healthy subjects (~88%), aged 18-80, who did not take any pharmaceutical drugs 
that could interfere with the USP; (ii) 29 (~12%) individuals affected by PCa, diagnosed by means 
of PSA > 4 and subsequent positive biopsy: symptoms of prostatic and urinary tract infection, 
results of TRUS biopsy, Gleason Score (from 2 to 10) and risk level (low, middle, high) were 
annotated. All the subjects belonging to the pathological class are older than 60 years.  
All samples were collected in the morning. Detailed description of the cohort is provided in the 
section 3.2. 
The choice of including only Caucasian subjects was to limit the UGT’s polymorphisms and the 
corresponding variability factor. Biometric (weight and height) and anamnestic information were 
collected from all individuals. PCa patients submitted to pharmacological treatments were excluded 
from the study. All subjects provided a signed informed consent to donate urine (protocol number 
0019267, approval of Ethical Committee of the San Luigi Hospital of Orbassano, Turin). The 
collected samples were frozen at 20°C and analyzed within the following 6 weeks. For each urine 
sample, 16 EAAS were detected, plus formestane and 5β-androstan-3,17-dione, viz. a marker of 
microbial degradation. Moreover, 5 steroid concentration ratios were calculated (i.e. T/E, A/T, 
A/Etio, 5α-adiol/5β-adiol and 5α-adiol/E). The microbial degradation did not occur for any sample 
(i.e. 5β-androstan-3,17-dione/Etio lower than 0.1), so the final dataset was constituted by 241 rows 
(subjects) and 22 columns (variables). 
 
2.7 CHEMOMETRICS 
 
A multivariate regression model was developed to study the correlation existing between the 
chronological age of healthy male individuals and their USP. The healthy subjects dataset used for 
the regression was constituted by a X matrix of dimensions 212 (i.e. number of the subjects)  22 
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variables and a Y vector of the responses (i.e., the age of the tested subjects). A logarithmic 
transformation was applied to the X matrix in order to correct the non-normal distribution of the 
data into Gaussian distributions, manageable by the regression algorithms. The dataset was split 
into a training (80% of the dataset) and a test set, using the Kennard-Stone’s algorithm [35,36]. 
Then, a variables selection was executed by means of genetic algorithms (GA) in the stepwise 
forward mode [37]. 
A Kernel-based Partial Least Squares (K-PLS) algorithm was used to calculate the regression model 
[38,39]. The model was submitted to double validation: during the procedure of model building, a 
cross-validation (CV) was performed (i.e. 20% of randomly chosen data were left out and used to 
test the prediction capability of the model); the most favourable model was chosen as the one with 
the lowest root-mean-square error in cross-validation (RMSECV). Then, an external validation was 
performed by predicting the response of the test set, and the root-mean-square error in prediction 
(RMSEP) was calculated. 
The model was subsequently tested on the dataset of subjects affected by PCa (29 rows  22 
columns) and the new RMSEP was compared with the one obtained from the healthy subjects. In 
order to exclude the age-related bias from the data, a preliminary classification model was 
subsequently developed on a homogeneous sub-set of individuals (aged 60-80) with the purpose of 
evaluating the proficiency of USP to discriminate healthy individuals from PCa patients. The model 
was optimized in CV by venetian blind strategy with 5 elimination groups, and selecting the one 
with best RMSECV. 
Matlab version R2013b was employed to perform the data pre-treatment, GA and the regression 
models. The PLS-Toolbox 8.0 was used for the classification purposes [40]. 
 
3. RESULTS AND DISCUSSION 
 
3.1 VALIDATION OF THE ANALYTICAL METHOD 
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In the lower calibration range, the linear model provided the best calibration for 11 analytes and the 
quadratic model for the others. A constant 1/x
2
 weighting factor was used for all calibrations, after 
the results of calibration data-points proved to have heteroscedastic distribution. All the validation 
results and calibration equations are reported in the Supplemental Material (Tables 3-8), together 
with LOD and LOQ values. Retention time precision, selectivity and specificity proved to be 
satisfactory, and no interfering signals were detected at the retention times of the target analytes. 
Trueness, intra- and inter-assay precision results turned out adequate, as the percent bias and CV% 
values were lower than 15.0% at all the tested concentration levels. 
Both extraction recovery and matrix effect turned out satisfactory (i.e. higher than 80% and lower 
than 120%) for all the target EAAS (Supplementary Tables 5-6). Lastly, absence of any carry-over 
effect was observed. 
 
3.2 UNIVARIATE EXPLORATION OF THE HEALTHY POPULATION’S DATASET 
 
The 212 healthy individuals were distributed over the investigated range of age as follows: 
- age range 20 – 39 yrs: 53 individuals; 
- age range 40 – 59 yrs: 59 individuals; 
- over 60 yrs: 100 individuals 
The number of variables composing the USP was reduced from 22 to 20, because the analytical 
signal for 7α-OH-testosterone and 4-OH-androstendione was always below the LOD. The general 
age-related trend shows a decrease of the urinary concentration for almost all steroids, as is evident 
in boxplots reported in Figure 1. More specifically, both A and Etio concentrations proved to 
decrease considerably with the aging. A significative decrease was also observed for 5α-Adiol and 
DHEA. For all the other steroids, a less-pronounced lowering of the median value is detected in the 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
high range of age. On the other hand, the urinary steroidal ratios do not show the same regular 
trend, with most median values nearly stable among the three ranges of age. 
 
3.3 REGRESSION MODEL AND PLS-DISCRIMINANT ANALYSIS  
 
A K-PLS regression algorithm was preferred to the traditional PLS-R approach, since in K-PLS 
input variables are projected onto a high-dimensional feature space to deduce the non-linear 
component from the data. Then, K-PLS can be considered as a conventional PLS algorithm 
operating in the feature space [38,39]. 
The regression model was built on the reduced (80%) USP dataset of healthy individuals (i.e., 169 
subjects selected with the Kennard-Stone's algorithm to form the training set) after logarithmic 
(base-10) transformation and autoscaling. 
The variable selection, performed using a hybrid GA (multiple GA runs followed by a forward 
stepwise inclusion of the most frequently picked predictors), resulted in the selection of 8 important 
variables, including T, 5α-adiol, 5β-adiol, A, DHEA, 7β-OH-DHEA, T/E, and A/Etio. The best 
performing regression model - based on Gaussian Kernel type, with σ equal to 2.69 - provided 4 
latent variables, with R
2
 equal to 0.75 and RMSECV of 8.7. The model is reported in Figure 2.A, 
featuring the subjects age predicted from USP data as a function of their real chronological age. The 
data distribution shows good correlation, yielding a prediction error lower than 10 years. The 
difference between the observed slope of the blue straight line (0.747) and the one of the red line 
representing exact correlation (1.000) provides another measure of the prediction error. The 
modelled correlation occurring between the multivariate USP of the individuals and their age was 
validated further, using the test set constituted by 43 USP from the healthy individuals previously 
discarded by the Kennard-Stone’s algorithm. The data-points for each individual within the 
previous model is represented by red squares in Figure 2.B; a RMSEP of 13 was obtained. 
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A set of 29 individuals with prostatic malignancy was used to test the predictivity power of the 
regression model. In this case, the RMSEP was of 22 years, with bias and residuals values of 
18.26 and 83.79 respectively (Figure 2.C). To investigate the reason of this lowered prediction 
power, the boxplots related to the steroids concentrations for the PCa population and the healthy 
individuals were built and reported in Figure 3. Within the eight variables selected for the 
regression of Figure2, an increased expression of the six EAAS is observed in the PCa population, 
while the two concentration ratios show similar distributions. In contrast, a significant difference in 
the urinary concentrations of Etio and 4-OH-testosterone is evident (Figure 3). Consequently, a new 
regression model was built, that excluded T/E and A/Etio ratios and included Etio and 4-OH-
Testosterone concentrations. The new regression model performed worse than the original one in 
the age prediction, as is demonstrated by a R
2
 value of 0.67 (instead of 0.75), although it showed a 
similar RMSEP value (11 years). On the other hand, a remarkable improvement in the separation of 
the two populations distribution (i.e., healthy vs. PCa-affected) is clearly observed in Figure 2.D. 
Figure 4 illustrates the distribution of the error in prediction for both healthy and PCa-affected 
individuals in the first (Figure 2.A) and in second (Figure 2.B) regression model. For the healthy 
population the maximum of the curve that describes the error distribution remains almost 
unchanged, from 0 to 2 years, whereas the maximum of the error distribution for the PCa population 
increases from -22 (Figure 4.A) to -32 years (Figure 4.B), resulting in a noteworthy increase of the 
separation between the two populations. 
Taking into account that PCa mostly occurs in individuals older than 60 years, a more homogeneous 
population of healthy individuals with age ranging between 60 and 80 years was extracted from the 
whole dataset, and a new K-PLS model was built (Supplementary Material, Figure 2), using the 
same 8 variables selected for the second regression model. The R
2
 coefficient within this age 
interval drops to 0.3345, confirming that only a minor trend is present in the data distribution, 
allowing us not to consider the age-related bias in the USP interpretation. 
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The good separation of the two distributions reported in Figure 2.D induced us to investigate a 
multivariate approach to UPS data as a means to screen out PCa-affected individuals. A new 
dataset, composed by 83 healthy subjects older than 60 years and the 29 PCa-affected individuals, 
was split in training set (80%) and test set (20%). A classification model based on PLS discriminant 
analysis (PLS-DA) was developed using same variables selected for the second regression model. 
The PLS-DA model yielded excellent discrimination between the two groups, as is evident in 
Figure 5. The area under the curve (AUC) for the receiver operating characteristic (ROC) curves 
provides a value close to 0.99 in calibration and higher than 0.97 in CV, as is reported in Figure 6. 
The sensibility and specificity of the model for the class of pathological individuals are equal to 
96% and 94%, respectively, confirming the potential of the PLS-DA application to UPS data for the 
screening of prostate carcinoma. 
 
4. CONCLUSIONS 
 
The biosynthesis of EAAS is largely dependent on age, which - for male individuals - is reflected in 
a progressive modification of their urinary EAAS profile. As these profiles are considered in their 
multivariate expression, a strong linear correlation was found with the chronological age. 
Significant deviations from this relationship observed between chronological age and the 
“physiological age” derived from urinary EAAS profile may be symptomatic of a pathological 
condition, as we demonstrated for prostatic carcinoma. As a matter of fact, the regression model 
built from healthy subjects does not hold for individuals affected by PCa and this phenomenon can 
be attributed to the alteration of the EAAS biosynthesis caused by the prostatic pathology, which 
creeps over the effect of ageing and the other sources of variability. 
Restricting the data evaluation to the typical late age of PCa onset, the chronological evolution of 
the multivariate EAAS profile becomes negligible, enhancing the possibility to distinguish the 
pathological from healthy conditions by means of classification models. Indeed, supporting 
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evidence of the diagnostic potential of urinary EAAS profiles was obtained by applying the PLS-
DA classification algorithm to sub-sets of profiles obtained from over-60 healthy and pathological 
male subjects. Further improvements of the screening and diagnostic power of multivariate 
strategies to EAAS profiles interpretation could arise from larger sets of free and conjugated 
targeted EAAS and particularly from various untargeted analysis, allowed by both GC-MS and LC-
HRMS methods. Indeed, these preliminary results encourage us to undertake a systematic study on 
the screening potential of multivariate discriminant analysis applied to a wide set of urinary 
androgenic steroids and addressed to the identification of PCa and its distinction from both prostatic 
hyperplasia and non-pathological conditions. This analysis may support the traditional screening 
procedure, involving digital rectal examination, PSA determination and TRUS biopsy. 
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Table 1: Composition and concentration of analytes and internal standards in the working solutions. 
Solution Composition 
Concentration 
(μg/mL) 
MIX A 
T, E, 5α-adiol, 5β-adiol, DHEA, 5β-androstan-3,17-dione, 4-androsten-3,17-dione, 4,6-
androsten-3,17-dione, 7β-DHEA, 7α-OH-testosterone, 4α-OH-testosterone, 16α-OH-
androsten-3,17-dione, 5-androsten-3,17-diol, 6-testosterone, formestane, DHT 
10 
MIX B A, Etio 200 
MIX C 
testosterone glucuronide, 5α-dihydrotestosterone glucuronide, dehydroepiandrosterone 
glucuronide, epitestosterone glucuronide  
15 
ISTD1 testosterone-d3 10 
ISTD2 17-methyltestosterone 10 
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FIGURE LEGENDS 
 
Figure 1: Box-plots reporting the urinary steroid concentrations and their ratios for three age ranges: 20-39 y, 
40-59 y, and over 60 y, respectively. 
Figure 2: (A) K-PLS model over the reference population; (B) prediction of the test set composed by healthy 
individuals; (C) prediction of the test set constituted by subjects suffering from PCa; (D) prediction of the 
test set constituted by subjects suffering from PCa using the new selected variables.  
Figure 3: Box-plots reporting the eight biomarkers’ values selected in the regression of Figure 2A, plus 4-
OH-Testosterone and Etiocholanolone, limited to the “over 60” age-range and distinguished between healthy 
and PCa-affected populations. 
Figure 4: Histograms reporting the distributions of the errors in prediction for healthy and PCa populations 
for the first (A) and the second (B) regression models, reported in Figures 2C and 2D. 
Figure 5: PLS-DA model separating the healthy (blue dots) and PCa (green squares) populations in the age 
range over 60 years. 
Figure 6: ROC curves (left) and responses (right), both estimated and cross-validated, derived from the PLS-
DA model reported in Figure 5. 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
Figure 5
Click here to download high resolution image
Figure 6
Click here to download high resolution image
  
Supplementary Material
Click here to download Supplementary Material: Supplementary Material.docx
